ADAC pays $2 million as part of settlement Nuclear medicine vendorsADAC Laboratories and Elscint went down to the wire in their legalfight over gamma camera patents, but in the end decided to settleout of court rather than proceed to trial. As
Nuclear medicine vendorsADAC Laboratories and Elscint went down to the wire in their legalfight over gamma camera patents, but in the end decided to settleout of court rather than proceed to trial. As part of the settlement,Milpitas, CA-based ADAC will pay Elscint $2 million and both partieswill withdraw their respective lawsuits and refrain from furtherpatent litigation for 10 years.
Elscint, of Haifa, Israel, filed the patent suit in U.S. DistrictCourt in Maryland last year after winning a legal victory overSopha Medical on gamma camera patents (SCAN 9/8/93). Sopha paidElscint $7.75 million to settle that case.
Elscint found the going tougher against ADAC. Two Elscint motionsto prohibit ADAC from manufacturing cameras covered by the patentswere denied. More significantly, ADAC filed a countersuit againstElscint based on gamma camera patents ADAC acquired from PhilipsMedical Systems (SCAN 3/2/94).
The confrontation was ripe for a settlement, but the two sidesremained far apart as recently as August, when ADAC chairman andco-CEO Stanley Czerwinski announced that Elscint appeared to beintent on going to trial. ADAC at that time took a $5.5 millioncharge in preparation for legal expenses expected to be incurredin a lengthy court battle.
Just days before the trial was scheduled to begin, however,the companies announced that they had come to terms. Both partieswithdrew their lawsuits and signed an agreement prohibiting furtherpatent litigation in the nuclear medicine and digital subtractionangiography fields for the next decade. In addition, ADAC agreedto use Elscint as a preferred supplier of multi-format imagingcameras. ADAC also agreed to pay Elscint $2 million, a hefty sumof money but less than what the company could have spent in adrawn-out court battle.
"Both companies have recognized that the resources consumedin expensive legal battles are better utilized in improving theirrespective contribution to better and more cost-effective healthcare," Czerwinski said. "We at ADAC are extremely pleasedthat this matter is now behind us and that we can return all ofour attention to that vital task."
ADAC revised its recent estimate of year-end adjustments toaccount for the end of the Elscint litigation. The company increasedits estimate of the extraordinary one-time net gain it will reportfor the fourth quarter to 21¢ a share from 18¢ a shareannounced on Aug. 29. The figure will be in addition to whateveroperating results the company posts. The write-off for legal costsis expected to be reduced to $4.5 million from the $5.5 millionannounced earlier.
In the wake of the settlement, the question is whether Elscintwill pursue similar patent claims against other manufacturersof nuclear medicine equipment. Its disputes with Sopha and ADAChave earned the firm nearly $10 million in the past two years.
Elscint president and CEO Jonathan Adereth said the companywill continue its policy of entering into intellectual propertycooperation agreements with other firms, while at the same time"diligently protecting its expanding patent portfolio."
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.